Repositrak, Inc. (TRAK) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the unaudited quarterly report (Form 10-Q) for Repositrak, Inc. for the three months ended September 30, 2025. Repositrak is a Software-as-a-Service (SaaS) company providing B2B e-commerce, compliance, traceability, and supply chain management solutions. The company operates under a "hub and spoke" model, primarily serving food retailers, wholesalers, and distributors to ensure compliance with regulations such as the Food Safety Modernization Act (FSMA).
Key Financial Metrics
| Metric | Q1 2026 (Sep 30, 2025) | Q1 2025 (Sep 30, 2024) |
|---|---|---|
| Revenue | $5,971,467 | $5,441,142 |
| Net Income | $1,819,529 | $1,665,155 |
| Diluted EPS | $0.09 | $0.08 |
| Operating Cash Flow | $1,538,447 | $1,868,900 |
| Cash & Equivalents | $28,794,806 | $25,790,206 |
| Total Debt | $457,304 (Leases) | $509,973 (Leases) |
| Working Capital | $28,899,777 | $28,154,682 |
Margins: Gross margin improved to approximately 86% (Cost of revenue was 14% of revenue) compared to 84% in the prior year. Operating margin was approximately 32%.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by 10% ($530,325) year-over-year, driven by growth in recurring subscription revenue across compliance, supply chain, and traceability lines.
- Profitability: Net income increased by 9% to $1.82 million. Income from operations rose to $1.89 million.
- Expense Management: Cost of revenue decreased slightly (1%) due to capitalization of development costs. Sales and marketing expenses increased 5% due to higher commissions and traceability marketing. General and administrative expenses increased 6% due to higher insurance and benefit costs.
- Cash Flow: Operating cash flow decreased 18% to $1.54 million, primarily due to an increase in accounts receivable and prepaid expenses, despite higher net income.
- Debt Reduction: The company terminated its revolving credit facility in March 2024 and currently holds zero bank debt. Total liabilities consist primarily of financing leases.
Guidance, Outlook, and Risks
- Regulatory Drivers: The FDA extended the FSMA 204 traceability compliance deadline to July 2028. However, major retailers are mandating earlier adoption (some by June 2025), driving demand for Repositrak's traceability solutions.
- Dividends: The Board declared a quarterly cash dividend of $0.02 per share (annualized $0.08), representing a 10% increase from the prior quarter. This is the third consecutive 10% increase since the dividend program began.
- Shareholder Returns: The company continued its share repurchase program, buying back 8,715 shares for $149,985. Additionally, $749,995 of Series B Preferred Stock was redeemed. Approximately $2.85 million remains available for future preferred stock redemption.
- Risks: The company notes that future interest income may decline as the Federal Reserve cuts rates. There are no new material legal proceedings or risk factors disclosed beyond those in the annual 10-K.
Investor Verification Checklist
- Verify the sustainability of the 10% revenue growth rate given the extension of the FDA FSMA 204 deadline to 2028.
- Monitor the impact of declining interest rates on the company's investment income, which contributed significantly to "Other Income."
- Confirm the timeline for the full redemption of the remaining $2.85 million in Series B Preferred Stock.
- Review the increase in accounts receivable to ensure collection trends remain healthy despite the growth in longer-term contracts.
- Assess the capitalization of software development costs and its impact on future depreciation/amortization expenses.